FDA approves Bevespi Aerosphere for COPD

The FDA has approved Bevespi Aerosphere for COPD.
The FDA has approved Bevespi Aerosphere for COPD.

The FDA has approved Bevespi Aerosphere (glycopyrrolate/formoterol fumarate 9 mcg/4.8 mcg) for chronic obstructive pulmonary disease (COPD). The drug, developed by AstraZeneca, is the first long-acting muscarinic antagonist/long-acting beta-2 agonist combination in a pressurized metered-dose inhaler (pMDI).

Bevespi Aerosphere is indicated for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.

Continue Reading Below

The drug was approved based on data from the PINNACLE 1, PINNACLE 2, and PINNACLE 3 trials, which enrolled more than 3,700 patients with moderate to very severe COPD.

The trials showed that patients taking Bevespi Aerosphere had statistically significant improvements in morning pre-dose forced expiratory volume in 1 second at 24 weeks, compared with its mono-components and placebo. The drug also significantly improved peak forced expiratory volume in 1 second within 2 hours postdose and use of rescue medication.

The most common adverse reactions for patients taking Bevespi Aerosphere were urinary tract infection (2.6% vs 2.3% with placebo) and cough (4.0% vs 2.7% with placebo).

Bevespi Aerosphere is not indicated for the treatment of asthma or for acute bronchospasm relief.

The full prescribing information is available from the FDA: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdf.

Loading links....
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in COPD Information Center

Sign Up for Free e-newsletters